Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure, Heart Failure, Diastolic
Data-Driven Phenotyping in Heart Failure With Preserved Ejection Fraction
The goal of this observational study is to learn how people with Heart Failure with Preserved Ejection Fraction (HFpEF) can be grouped into different "phenotypes" based on their clinical information.
- Conditions
- Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- NCT07429396
- Where
- 2 sites in Portugal
- Volunteers
- 200 people
- Sponsor
- Instituto Politécnico de Leiria
Heart Failure With Preserved Ejection Fraction
Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study including approximately 130 randomized HF patients with heart failure with mildly reduced or preserved ejection fraction (LVEF ≥45%), to assess…
- Trial name
- REMOD-REVERT (NCT05953831)
- Testing
- CDR132L
- Sponsor
- Cardior Pharmaceuticals GmbH
Heart Failure With Preserved Ejection Fraction, Diabete Type 2
The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction
a prospective open-label, randomized controlled study to evaluate the efficacy of the addition of metformin to SGLT2 in diabetic patient with preserved ejection fraction
- Trial name
- NCT06080802
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- October University for Modern Sciences and Arts
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)
Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study
The purpose of this clinical study is to assess the safety and effectiveness of the Atrial Flow Regulator in the treatment of subjects, 18 years of age or older, who have symptomatic heart failure with preserved ejection fraction…
- Trial name
- FROST-HF (NCT05136820)
- Testing
- Atrial Flow Regulator
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Occlutech International AB
Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction
Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors generally and empagliflozin specifically have shown cardiovascular benefits in patients with heart failure (HF), but the underlying mechanisms remain unclear.
- Conditions
- Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus
- Trial name
- NCT05139472
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure With Preserved Ejection Fraction, Pulmonary Disease
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)
Heart failure with preserved ejection fraction (HFpEF) accounts for over 50% of heart failure cases in the United States, affecting a primarily elderly population.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
- Trial name
- NCT01354613
- Testing
- Dobutamine, Amlodipine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
Heart Failure With Preserved Ejection Fraction, Sleep Disordered Breathing
Heart Function in Patients Assessed for Sleep Apnoea
This study aims to determine the prevalence and prognosis of heart failure with preserved ejection function (HFpEF) among patients being assessed for sleep disordered breathing (SDB).
- Conditions
- Heart Failure With Preserved Ejection Fraction, Sleep Disordered Breathing, Heart Failure With Normal Ejection Fraction, Obstructive Sleep Apnea
- Trial name
- NCT03226652
- Where
- United Kingdom
- Volunteers
- 101 people
- Sponsor
- Imperial College London
Heart Failure
Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction
A randomized, double-blinded, placebo-controlled crossover study to assess effect of isosorbide mononitrate with dose up-titration on activity tolerance as assessed by (hip-worn, tri-axial) accelerometry.
- Trial name
- NEAT-HFpeF (NCT02053493)
- Testing
- Isosorbide Mononitrate
- Where
- 22 sites in United States
- Volunteers
- 110 people
- Sponsor
- Adrian Hernandez
Heart Failure With Preserved Ejection Fraction
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism [Empagliflozin (Empa)], with and without additional supplements that increase perfusion and fatty acid oxidation…
- Trial name
- SAK (NCT05138575)
- Testing
- Empagliflozin + Potassium Chloride, Empagliflozin + Potassium Nitrate
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Pennsylvania
Heart Failure With Preserved Ejection Fraction, Obesity
The Effect of Obesity and Weight Loss in Heart Failure With Preserved Ejection Fraction
This study looks at the effects of weight loss in people who have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese.
- Trial name
- OWL-HFPEF (NCT05878912)
- Testing
- Diet intervention
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- University of Oxford
Heart Failure With Normal Ejection Fraction, Ferropenic Anemia
Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)
The purpose of the study is to evaluate whether the administration of iron to patients with heart failure and preserved ejection fraction results in an improvement of symptoms and functional class, in addition to evaluating…
- Trial name
- PREFER-HF (NCT03833336)
- Testing
- Ferric carboxymaltose, Ferroglycine Sulfate, Sucrosomial Iron
- Where
- 2 sites in Spain
- Volunteers
- 72 people
- Sponsor
- Institut de Recerca Biomèdica de Lleida
Atrial Functional Mitral Regurgitation
Safety and Efficacy of Transcatheter Edge-to-Edge Repair for Atrial Functional Mitral Regurgitation
This study is a prospective, randomized, parallel-control, open-label, multicenter clinical trial. Eligible subjects will be randomized in a 1:1 ratio to the Device group (Interventional group) or to no Device group (Control…
- Trial name
- STAR (NCT07414225)
- Testing
- Transcatheter Edge-to-Edge Repair, Guideline-Directed Medical Therapy (GDMT) for cardiovascular disease
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Anzhen Hospital
Heart Failure With Preserved Ejection Fraction, Prognathism
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Factors influencing the prognosis of patients with heart failure with preserved ejection fraction (HFpEF) have been extensively studied.
- Trial name
- NCT06379152
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Chongqing Medical University
Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF)
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in Chinese subjects with heart failure with ejection fraction retention/mild ejection fraction…
- Conditions
- Obesity, Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Mildly Reduced Ejection Fraction
- Trial name
- NCT06862908
- Testing
- IBI362
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
HFpEF - Heart Failure With Preserved Ejection Fraction
The Gut Microbiota and Metabolites in HFpEF
Heart failure (HF) with preserved ejection fraction (HFpEF) has emerged as a critical public health concern. The annual mortality rate for HFpEF is approximately 15%, accompanied by a re-hospitalization rate of nearly 80%.
- Trial name
- NCT06645535
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
- Trial name
- AMBER-HFpEF (NCT06793371)
- Testing
- CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
- Where
- 26 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cytokinetics
Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction (HFPEF)
AI-based Echocardiography for Detection of Cardiac Amyloidosis
Cardiac amyloidosis is characterized by deposition of misfolded protein in the myocardium causing mainly heart failure symptoms with preserved left ventricular ejection fraction.
- Conditions
- Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction (HFPEF), Left Ventricular Hypertrophy
- Trial name
- ORCHESTRA (NCT07529860)
- Testing
- AI-based echocardiogram
- Volunteers
- 200 people
- Sponsor
- Germans Trias i Pujol Hospital
Pulmonary Hypertension, Diastolic Heart Failure
Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure
Heart failure with preserved ejection fraction (HFpEF), is one of the leading causes of pulmonary hypertension (PH). Despite the severity of this disease, no established treatments exist for this class of PH.
- Conditions
- Pulmonary Hypertension, Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT02053246
- Testing
- Nebivolol
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Florida
Hypertension Pulmonary Secondary, Heart Failure, Right Sided
Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects
- Conditions
- Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
- Trial name
- HELP (NCT03541603)
- Testing
- Levosimendan
- Where
- 16 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tenax Therapeutics, Inc.